BrainStorm Senior Management to Present at BIO 2019
May 28 2019 - 12:00AM
BrainStorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading
developer of adult stem cell therapeutics for neurodegenerative
disease, today announced members of the Senior Management Team will
have an expanded presence at BIO International Convention 2019 held
in Philadelphia, June 3-6.
President & CEO, Chaim Lebovits, will
present a corporate overview of BrainStorm’s business trajectory,
an update on the Company’s clinical trials and outline the
Company’s overall investment proposition on Tuesday, June 4, 2019
at 1:45 PM EDT, in Theater 2. CMO and COO, Ralph Kern, MD,
MHSc, will serve as an expert panelist during a Round Table
sponsored by industry leader Informa Pharma Intelligence. The
Round Table discussion will feature scientific and medical
specialists, who will discuss the many challenges and issues facing
the unmet medical needs of Rare Diseases. The Round Table
will be held on June 4th at the Windsor Suites Hotel.
“BrainStorm has made significant progress on all
fronts since BIO 2018. Management looks forward to participating in
BIO 2019 and we will provide a comprehensive company update.
We also anticipate a full schedule of meetings with investors,
potential business partners and members of the media. With
over 16,000 industry leaders projected to attend BIO 2019, we are
excited to share our progress with such an extensive audience of
industry peers,” said Chaim Lebovits, President & CEO of
BrainStorm.
About BrainStorm Cell Therapeutics
Inc. BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm is currently enrolling a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA
clearance to initiate a Phase 2 open-label multicenter trial in
progressive Multiple Sclerosis. The Phase 2 study of autologous
MSC-NTF cells in patients with progressive MS (NCT03799718) started
enrollment in March 2019. For more information, visit the company's
website at www.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended
to identify these forward-looking statements. The potential risks
and uncertainties include, without limitation, risks associated
with BrainStorm's limited operating history, history of losses;
minimal working capital, dependence on its license to Ramot's
technology; ability to adequately protect the technology;
dependence on key executives and on its scientific consultants;
ability to obtain required regulatory approvals; and other factors
detailed in BrainStorm's annual report on Form 10-K and quarterly
reports on Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTS
Corporate: Uri YablonkaChief Business Officer BrainStorm Cell
Therapeutics Inc.Phone: +1 646.666.3188 uri@brainstorm-cell.com
Media:Sean LeousWestwicke/ICR PR Phone:
+1.646.677.1839sean.leous@icrinc.com
Investors:Michael LevitanSolebury TroutPhone:
+1.646.378.2920mlevitan@soleburytrout.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2024 to May 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From May 2023 to May 2024